HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Homeostatic tissue responses in skin biopsies from NOMID patients with constitutive overproduction of IL-1β.

Abstract
The autoinflammatory disorder, Neonatal-onset Multisystem Inflammatory Disease (NOMID) is the most severe phenotype of disorders caused by mutations in CIAS1 that result in increased production and secretion of active IL-1β. NOMID patients present with systemic and organ-specific inflammation of the skin, central nervous system and bone, and respond dramatically to treatment with IL-1 blocking agents. We compared the cellular infiltrates and transcriptome of skin biopsies from patients with NOMID (n = 14) before treatment (lesional (LS) and non-lesional (pre-NL) skin) and after treatment (post-NL) with the IL-1 blocker anakinra (recombinant IL-1 receptor antagonist, Kineret®, Swedish Orphan Biovitrum AB, SOBI), to normal skin (n = 5) to assess tissue responses in the context of untreated and treated disease. Abundant neutrophils distinguish LS skin from pre-NL and post-NL skin. CD11c(+) dermal dendritic cells and CD163(+) macrophages expressed activated caspase-1 and are a likely source of cutaneous IL-1 production. Treatment with anakinra led to the disappearance of neutrophils, but CD3(+) T cells and HLA-DR(+) cells remained elevated. Among the upregulated genes IL-6, IL-8, TNF, IL-17A, CCL20, and the neutrophil defensins DEFA1 and DEFA3 were differentially regulated in LS tissues (compared to normal skin). Important significantly downregulated pathways in LS skin included IL-1R/TLR signaling, type I and II cytokine receptor signaling, mitochondrial dysfunction, and antigen presentation. The differential expression and regulation of microRNAs and pathways involved in post-transcriptional modification were suggestive of epigenetic modification in the chronically inflamed tissue. Overall, the dysregulated genes and pathways suggest extensive "adaptive" mechanisms to control inflammation and maintain tissue homeostasis, likely triggered by chronic IL-1 release in the skin of patients with NOMID.
AuthorsPamela Aubert, Mayte Suárez-Fariñas, Hiroshi Mitsui, Leanne M Johnson-Huang, Jamie Lynn Harden, Katherine C Pierson, Joseph G Dolan, Inna Novitskaya, Israel Coats, Jacob Estes, Edward W Cowen, Nicole Plass, Chyi-Chia Richard Lee, Hong-Wei Sun, Michelle A Lowes, Raphaela Goldbach-Mansky
JournalPloS one (PLoS One) Vol. 7 Issue 11 Pg. e49408 ( 2012) ISSN: 1932-6203 [Electronic] United States
PMID23226210 (Publication Type: Journal Article, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't)
Chemical References
  • Antigens, CD
  • HLA-DR Antigens
  • Interleukin 1 Receptor Antagonist Protein
  • Interleukin-1beta
  • MicroRNAs
  • Receptors, Interleukin-1
  • Caspase 1
Topics
  • Adolescent
  • Adult
  • Antigens, CD (genetics, immunology)
  • Biopsy
  • Caspase 1 (genetics, immunology)
  • Child
  • Child, Preschool
  • Cryopyrin-Associated Periodic Syndromes (drug therapy, genetics, immunology, pathology)
  • Epigenesis, Genetic (drug effects, immunology)
  • Female
  • Gene Expression (drug effects, immunology)
  • HLA-DR Antigens (genetics, immunology)
  • Homeostasis (drug effects, genetics, immunology)
  • Humans
  • Interleukin 1 Receptor Antagonist Protein (pharmacology, therapeutic use)
  • Interleukin-1beta (antagonists & inhibitors, genetics, immunology)
  • Langerhans Cells (drug effects, immunology, pathology)
  • Macrophages (drug effects, immunology, pathology)
  • Male
  • MicroRNAs (genetics, immunology)
  • Neutrophils (drug effects, immunology, pathology)
  • Receptors, Interleukin-1 (antagonists & inhibitors, genetics, immunology)
  • Signal Transduction (drug effects)
  • Skin (drug effects, immunology, pathology)
  • T-Lymphocytes (drug effects, immunology, pathology)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: